New hope for tough leukemia: DASATINIB trial targets Non-Responders

NCT ID NCT06055621

First seen Mar 15, 2026 · Last updated Jun 16, 2026 · Updated 12 times

Summary

This study tests a drug called DASATINIB in people with acute myeloid leukemia (AML) whose cancer did not improve after standard treatment with VENETOCLAX and AZACITIDINE. About 35 adults who cannot have strong chemotherapy will take DASATINIB for up to 3 months. Doctors will check if the cancer shrinks or goes away using blood tests and bone marrow exams. The goal is to see if DASATINIB can control the leukemia in these hard-to-treat patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institut Paoli Calmettes

    RECRUITING

    Marseille, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.